Find your path to Sarah
834 people in our graph share verified history with Sarah β schools, employers, funds. One of them is your warm intro.
About
Sarah Meibusch is Partner and Head of Healthcare at OneVentures, bringing over 20 years of enterprise-level business leadership across science and technology sectors in both for-profit and not-for-profit organizations. Her experience includes negotiating corporate transactions, research partnerships, licensing agreements, and mergers and acquisitions across corporate, government, and university environments, as well as managing corporate actions for NASDAQ and ASX-listed companies. She has held roles at organizations including Vaxxas, BiVACOR, Shire Pharmaceuticals, and the University of Queensland.
ContactΒ· self-published, not guessed
Experience
- OneVenturesPartner, Head of Healthcarecurrent2025 β present
- OneVenturesPartnercurrent2022 β present
- OneVenturesPrincipal2019 β 2022
- OneVenturesInvestment Manager2017 β 2018
- VaxxasChair of the Board of Directorscurrent2025 β present
- VaxxasBoard Alternate Director and Observer2020 β 2025
- Vertero Therapeutics, Inc.Non Executive Directorcurrent2021 β present
- Vertero Therapeutics, Inc.Chair of the Board of Directors2023 β 2025
- Kira Biotech Pty LtdNon Executive Directorcurrent2020 β present
- Kira Biotech Pty LtdNonexecutive Director - Chair of the Board2019 β 2020
- PROTA THERAPEUTICS PTY LTDBoard Alternate Director and Observercurrent2019 β present
- BearTrap Solutions Pty LtdPrincipalcurrent2009 β present
- Life Sciences Queensland LimitedNonexecutive Director2019 β 2025
- Queensland Alliance for Agriculture and Food Innovation (QAAFI)Member Of The Board Of Advisors2017 β 2024
- Queensland Alliance for Agriculture and Food Innovation (QAAFI)Deputy Director2012 β 2017
- Blade TherapeuticsBoard Observer2019 β 2023
- Paragen BioBoard Observer2018 β 2020
- Shire PharmaceuticalsContractor - Asia Business Development2011 β 2016
- Cooperative Research Centre for Beef Genetic Technologies (Beef CRC)Chief Operating Officer, Commercialisation2009 β 2012
- The Australian VoicesNon Executive Director2011
- Progen PharmaceuticalsVice President of Business Development2003 β 2009
- Pyxis GenomicsManager of Business Development2001 β 2003
Skills & more
+12 more
OncologyDrug DevelopmentLicensingBusiness StrategyDrug DiscoveryMergers & AcquisitionsClinical DevelopmentCorporate DevelopmentGenomicsR&DRegulatory AffairsFDALanguages English Β· German
From Sarah's professional profile.
Colleagues at OneVentures
Frequently asked questions
- Who is Sarah Meibusch?
- Sarah Meibusch is Partner and Head of Healthcare at OneVentures, bringing over 20 years of enterprise-level business leadership across science and technology sectors in both for-profit and not-for-profit organizations. Her experience includes negotiating corporate transactions, research partnerships, licensing agreements, and mergers and acquisitions across corporate, government, and university environments, as well as managing corporate actions for NASDAQ and ASX-listed companies. She has held roles at organizations including Vaxxas, BiVACOR, Shire Pharmaceuticals, and the University of Queensland.
- Where does Sarah Meibusch work?
- Sarah Meibusch is Partner at OneVentures.
- Where did Sarah Meibusch go to school?
- Sarah Meibusch studied at Australian Institute of Company Directors (Graduate of the Australian Company Directors Course (GAICD)); Harvard Business School (Executive Education Program, Negotiation and Competitive Decision Making); Cornell University (Master's degree, Genome Sciences/Genomics cattle).
Same school
Also attended Australian Institute of Company Directors234
+ 228 more
Also attended Harvard Business School2,000
+ 1,994 more
Also attended Cornell University1,413
+ 1,407 more
Also attended The University of Queensland212
+ 206 more
Shared employers
Also worked at OneVentures13
+ 7 more
Also worked at Vertero Therapeutics, Inc.7
+ 1 more
Also worked at Queensland Alliance for Agriculture and Food Innovation (QAAFI)1
Also worked at Shire Pharmaceuticals38
+ 32 more






















































